Human cells, grown in a dish
GHK-Cu helped cultured human fibroblasts make more collagen. Fibroblasts are cells that help build connective tissue. Collagen is a protein that gives that tissue strength.
That's a useful clue about what the ingredient can do in that setting. But “human” describes the cells, not a group of people receiving treatment. Nobody's complexion was measured, and the experiment didn't include GLOW.
So if you arrived hoping for smoother or brighter skin, this study can't predict that result. It also can't tell you whether adding BPC-157 and TB-500 would help, make no difference or create problems.
A laboratory result can be worth following up. It doesn't have to settle the question about your skin.
A healing tendon, in a rat
In an experiment involving rats, BPC-157 helped cut Achilles tendons heal. The researchers measured things such as tendon strength and function. This helps explain the recovery claims that follow the ingredient around.
The catch isn't a small technicality. The animals had a specific injury chosen for the experiment. A person with a sore shoulder is a different situation, and the study didn't test a three-ingredient blend.
If you're comparing summaries, check who or what received treatment. In this study, the rats are a detail that changes the answer.
A review of BPC-157 found little human research and called for stronger trials. It described the peptide as investigational: still being studied, without established treatment evidence. The encouraging animal result doesn't remove that gap.
A human study of a different substance
Thymosin beta-4 was studied through intravenous infusions in healthy volunteers. Intravenous means into a vein. The short study recorded infrequent mild or moderate adverse events and no serious ones. An adverse event is a health problem reported during a study; it isn't necessarily caused by the treatment.
It used the whole protein. TB-500 is a small fragment of it, with a chemical cap added. They aren't interchangeable, so those safety findings don't become a safety record for TB-500 or GLOW.
Even for the whole protein, a small, short study can't settle rare problems or long-term safety. It tells us what happened to those volunteers during that study.
That's how far these three examples reach: cells, rats, and people given a different substance. None tested GLOW. The study-amount page follows the same distinctions when a number enters the story, and the effects page gives the remaining safety questions more space.